Research programme: immune disorder therapeutics - Oncobiologics

Drug Profile

Research programme: immune disorder therapeutics - Oncobiologics

Alternative Names: ONS-1210; ONS-1220; ONS-3015

Latest Information Update: 14 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncobiologics
  • Class Bispecific antibodies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 14 Aug 2013 Early research is ongoing in Crohn's disease, Psoriasis, Rheumatoid arthritis and Ulcerative colitis in USA
  • 17 Oct 2011 Early research in Crohn's disease, Psoriasis, Rheumatoid arthritis and Ulcerative colitis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top